Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 5
1968 8
1970 2
1971 4
1973 1
1974 3
1975 4
1977 1
1978 3
1979 2
1980 3
1981 2
1982 1
1983 3
1987 1
1988 1
1995 1
1996 1
2009 2
2010 1
2013 1
2014 1
2015 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Slimming and sleep.
Silverstone JT. Silverstone JT. Br Med J. 1968 Apr 20;2(5598):175. doi: 10.1136/bmj.2.5598.175-b. Br Med J. 1968. PMID: 5641992 Free PMC article. Clinical Trial. No abstract available.
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
Cercato C, Roizenblatt VA, Leança CC, Segal A, Lopes Filho AP, Mancini MC, Halpern A. Cercato C, et al. Int J Obes (Lond). 2009 Aug;33(8):857-65. doi: 10.1038/ijo.2009.124. Epub 2009 Jun 30. Int J Obes (Lond). 2009. PMID: 19564877 Clinical Trial.
OBJECTIVE: To evaluate the efficacy of diethylpropion on a long-term basis, with emphasis in cardiovascular and psychiatric safety aspects. ...From baseline to month 12, the mean weight loss produced by diethylpropion was 10.6% (8.3%). Participants in the placebo gr …
OBJECTIVE: To evaluate the efficacy of diethylpropion on a long-term basis, with emphasis in cardiovascular and psychiatric safety as …
Drugs and sleep.
Oswald I. Oswald I. Br Med J. 1968 Jun 1;2(5604):559. doi: 10.1136/bmj.2.5604.559-a. Br Med J. 1968. PMID: 4881584 Free PMC article. Clinical Trial. No abstract available.
A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice.
Vallé-Jones JC, Brodie NH, O'Hara H, O'Hara J, McGhie RL. Vallé-Jones JC, et al. Pharmatherapeutica. 1983;3(5):300-4. Pharmatherapeutica. 1983. PMID: 6844367 Clinical Trial.
A study was carried out in general practice to compare the effectiveness and tolerance of phentermine and diethylpropion in helping patients more than 20% above their desirable weight to lose weight. ...There were significant reductions in blood pressure and heart rate in …
A study was carried out in general practice to compare the effectiveness and tolerance of phentermine and diethylpropion in helping p …
Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial.
Soto-Molina H, Pizarro-Castellanos M, Rosado-Pérez J, Rizzoli-Córdoba A, Lara-Padilla E, del Valle-Laisequilla CF, Reyes-García JG. Soto-Molina H, et al. Int J Clin Pharmacol Ther. 2015 Jul;53(7):541-9. doi: 10.5414/CP202135. Int J Clin Pharmacol Ther. 2015. PMID: 26073353 Clinical Trial.
Amfepramone, also known as diethylpropion, is an anorectic drug used for the short-term treatment of obesity; however, its efficacy and safety during periods greater than 3 months has been scarcely studied. ...
Amfepramone, also known as diethylpropion, is an anorectic drug used for the short-term treatment of obesity; however, its efficacy a …
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
Jasinski DR, Krishnan S. Jasinski DR, et al. J Psychopharmacol. 2009 Jun;23(4):419-27. doi: 10.1177/0269881109103113. Epub 2009 Mar 27. J Psychopharmacol. 2009. PMID: 19329547 Clinical Trial.
A single-centre, double-blind, randomised, placebo-controlled, 6-period crossover study evaluated the abuse potential of single oral doses of 50, 100 (equivalent to 40 mg d-amphetamine), and 150 mg LDX, 40 mg d-amphetamine and 200 mg diethylpropion in 36 individuals with a …
A single-centre, double-blind, randomised, placebo-controlled, 6-period crossover study evaluated the abuse potential of single oral doses o …
Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study.
Ryan DH, Johnson WD, Myers VH, Prather TL, McGlone MM, Rood J, Brantley PJ, Bray GA, Gupta AK, Broussard AP, Barootes BG, Elkins BL, Gaudin DE, Savory RL, Brock RD, Datz G, Pothakamuri SR, McKnight GT, Stenlof K, Sjöström LV. Ryan DH, et al. Arch Intern Med. 2010 Jan 25;170(2):146-54. doi: 10.1001/archinternmed.2009.508. Arch Intern Med. 2010. PMID: 20101009 Clinical Trial.
The IMI group recommendations included a 900-kcal liquid diet for 12 weeks or less, group behavioral counseling, structured diet, and choice of pharmacotherapy (sibutramine hydrochloride, orlistat, or diethylpropion hydrochloride) during months 3 to 7 and continued use of …
The IMI group recommendations included a 900-kcal liquid diet for 12 weeks or less, group behavioral counseling, structured diet, and choice …
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Suplicy H, Boguszewski CL, dos Santos CM, do Desterro de Figueiredo M, Cunha DR, Radominski R. Suplicy H, et al. Int J Obes (Lond). 2014 Aug;38(8):1097-103. doi: 10.1038/ijo.2013.225. Epub 2013 Nov 29. Int J Obes (Lond). 2014. PMID: 24287940 Clinical Trial.
CONTEXT: No long-term studies have compared centrally acting drugs for treating obesity. OBJECTIVE: To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss. ...
CONTEXT: No long-term studies have compared centrally acting drugs for treating obesity. OBJECTIVE: To compare the efficacy and safety of …
54 results